Navigation Links
Malaria Drug Promising Against Cancer
Date:12/26/2007

60-year-old drug chloroquine eliminated certain malignancies in mice, researchers say

WEDNESDAY, Dec. 26 (HealthDay News) -- A common anti-malaria drug called chloroquine can also prevent the development of certain types of human cancers in mice, a U.S. study finds.

The finding may help lead to new kinds of cancer treatments, researchers say.

Scientists at The Scripps Institute and St. Jude's Children's Research Hospital found that chloroquine, which has been in use since 1946, blocked Burkitt lymphoma, a cancer of the lymphatic system, and ataxia telangiectasia (A-T), a rare immunodeficiency disease that predisposes people to cancer, especially leukemia and lymphoma.

The study was published online Dec. 20 by the Journal of Clinical Investigationand will appear in the January print edition.

"Our study shows that chloroquine inhibits the final steps of a pathway that is required for tumor cell survival and effectively eliminates cancer cells in mouse models that replicate human tumors," John Cleveland, chairman of the department of cancer biology at Scripps' campus in Jupiter, Fla., said in a prepared statement.

"The fact that the drug attacks premalignant cells, and cells that overexpress transcription factor MYC, a notorious contributor to tumorigenesis that is implicated in more than 70 percent of all cancers, makes the use of this drug very attractive for chemoprevention and cancer treatment," he said.

Much more research is required before these findings may lead to the development of new cancer drugs, he added.

More information

MedlinePlus has more about chloroquine.



-- Robert Preidt



SOURCE: Scripps Research Institute, news release, Dec. 20, 2007


'/>"/>
Copyright©2007 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Kenyan malaria success strengthens call for free insecticide-treated nets for all
2. MDS Pharma Services Wins Award for Management of Global Malaria Trial
3. How adhesive protein causes malaria
4. Malaria product portfolio would benefit from greater cohesion amongst stakeholders
5. USAID Announces First Malaria Communities Program Grants
6. Collaborative Drug Discovery, Inc. and St. Jude Childrens Research Hospital Make Malaria Research Data Available to Speed Drug Development
7. World Bank Group Report on Malaria in Africa Highlights Progress Towards Goal of Significantly Reducing Malaria Deaths
8. Sanofi Pasteur and Institut Pasteur Team up Against Malaria
9. Bill and Melinda Gates Call for New Global Commitment to Chart a Course for Malaria Eradication
10. Malaria No More and Sumitomo Chemical Help Protect 1.4 Million Kids from Malaria
11. Malaria Vaccine Shows Promise
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... Olathe, KS (PRWEB) , ... April 28, 2017 ... ... system have typically been previously exposed to more adverse experiences than children in ... have experienced trauma such as abuse, neglect or other family challenges. While no ...
(Date:4/28/2017)... ... April 28, 2017 , ... Early ... substantially improve drug safety and minimize the cost of development. In this webinar, ... inhibition using cell lines and for cardiac toxicity using induced pluripotent stem cells ...
(Date:4/28/2017)... ... April 28, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of ... the Creator responds to and which He does not. Yisrayl says with so many ... is the true name, but he says with a little Scripture, backed with a lot ...
(Date:4/28/2017)... ... 2017 , ... Intellitec Solutions announced the publication of a ... Dynamics GP solution that integrates to their PointClickCare EHR software package. With the ... Brooke Grove now has the capability to achieve its goal for a comprehensive ...
(Date:4/28/2017)... ... April 28, 2017 , ... Rob Lowe is a popular actor that ... his presence to an educational purpose as the host of the “Informed” series. The ... In a recent episode, the series focuses on thyroid cancer. , Although thyroid cancer ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017 Research and Markets ... - Innovation Driven by Rapidly Expanding Injectables Market and Increasing Usage ... offering. ... drug delivery technologies will rise from USD 20 Billion in 2015 ... Global Drug Delivery Technologies - Innovation Driven by Rapidly Expanding Injectables ...
(Date:4/20/2017)...  AbbVie (NYSE: ABBV), a global biopharmaceutical company, ... hepatitis C virus (HCV) infected patients with genotype ... cirrhosis (Child-Pugh A) achieved sustained virologic response at ... investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These high ... weeks of G/P treatment without ribavirin. Patients with ...
(Date:4/20/2017)... LUND, Sweden , April 20, 2017 /PRNewswire/ ... OTCQX: NEVPF) ("NeuroVive") today announced positive preclinical ... company,s preclinical compound for non-alcoholic steatohepatitis (NASH), ... NV556 has previously ... STAM™ NASH model. Today, NeuroVive,s scientists present ...
Breaking Medicine Technology: